Pharmacokinetics of flunixin meglumine in healthy foals less than twenty-four hours old

American Journal of Veterinary Research

Volumn 57, Issue 12, 1996, Pages 1759-1761

  Crisman, Mark V ^a   Wilcke, Jeff R ^a   Sams, Richard A ^b  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUNIXIN MEGLUMINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; FEMALE; HORSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEWBORN;

AGING; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLONIXIN; FEMALE; HORSES; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 0029821469     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Traub-Dargatz JL, Bertone JJ, Gould DH, et al. Chronic flunixin meglumine therapy in foals. Am J Vet Res 1988;49:7-12.
2. Carrick J, Papich M, Middleton D, et al. Clinical and pathological effects of flunixin meglumine administration to neonatal foals. Can J Vet Res 1989;53:195-201.
3. Semrad SD, Hardee GE, Hardee MM, et al. Flunixin meglumine given in small doses: pharmacokinetics and prostaglandin inhibition in healthy horses. Am J Vet Res 1985;46:2474-2479.
4. Lees P, Ewins CP, Taylor JBO, et al. Serum thromboxane in the horse and its inhibition by aspirin, phenylbutazone and flunixin. Br Vet J 1987;143:462-476.
5. Soma LR, Behrend E, Rudy J, et al. Disposition and excretion of flunixin meglumine in horses. Am J Vet Res 1988;49:1894-1898.
6. Toutain P, Autefage A, Legrand C, et al. Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modeling. J Vet Pharmacol Ther 1994;17:459-469.
7. Landoni MF, Lees P. Comparison of the anti-inflammatory action of flunixin and ketoprofen in horses applying PK/PD modeling. Equine Vet J 1995;27:247-256.
8. Chay S, Woods WE, Nugent T, et al. The pharmacology of nonsteroidal anti-inflammatory drugs in the horse: flunixin meglumine (Banamine). Equine Pract 1982;4:16-23.
9. Semrad SD, Sams RA, Ashcraft SM. Pharmacokinetics of and serum thromboxane suppression by flunixin meglumine in healthy foals during the first month of life. Am J Vet Res 1993;54: 2083-2087.
10. Wilcke JR, Crisman MV, Sams RA, et al. Pharmacokinetics of phenylbutazone in neonatal foals. Am J Vet Res 1993;54:2064-2067.
11. Semrad SD, Hardee GE, Hardee MM, et al. Low dose flunixin meglumine: effects on eicosanoid production and clinical signs induced by experimental endotoxaemia in horses. Equine Vet J 1987; 19:201-206.
12. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
13. Gibaldi M, Perrier D. Multicompartment models. In: J. Swarbrick J, ed. Drugs and the pharmaceutical sciences. 2nd ed. New York: Marcel Dekker, 1982;45-109.
14. Davis LE, Westfall BA, Short CR. Biotransformation and pharmacokinetics of salicylate in newborn animals. Am J Vet Res 1973;34:1105-1108.
15. Jensen RC, Fischer JH, Cwik MJ. Effect of age and training status on pharmacokinetics of flunixin meglumine in Thoroughbreds. Am J Vet Res 1990;51:591-594.
16. Bottoms GD, Fessler JF, Roesel OF, et al. Endotoxin-induced hemodynamic changes in ponies: effects of flunixin meglumine. Am J Vet Res 1981;42:1514-1518.
17. Moore J, Garner H, Shapland J, et al. Prevention of endotoxin-induced arterial hypoxaemia and lactic acidosis with flunixin meglumine in the conscious pony. Equine Vet J 1981;13:95-98.